Isaacsson Velho Pedro H, Castro Gilberto, Chung Christine H
Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Johns Hopkins Medical Institutions, 1550 Orleans Street CRB-2 Room 546, Baltimore, MD 21287-0014, USA; Department of Otolaryngology-Head and Neck Surgery, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Johns Hopkins Medical Institutions, 1550 Orleans Street CRB-2 Room 546, Baltimore, MD 21287-0014, USA.
Hematol Oncol Clin North Am. 2015 Dec;29(6):993-1009. doi: 10.1016/j.hoc.2015.07.006.
Based on currently available genomic data, most head and neck squamous cell carcinoma have few targetable aberrations and immediate clinical translation is challenging. However, potential therapeutic agents listed in this article need to be thoroughly evaluated because there are compelling scientific rationales supporting their development. Concerted effort is required to identify better predictive biomarkers of clinical benefit and improve the therapeutic index. Clinicians need to better understand resistance mechanisms, generate novel hypotheses for appropriate combination regimens and dosing schedules, develop more accurate model systems, and conduct innovative clinical trials.
基于目前可用的基因组数据，大多数头颈部鳞状细胞癌几乎没有可靶向的异常，并且立即进行临床转化具有挑战性。然而，本文列出的潜在治疗药物需要进行全面评估，因为有令人信服的科学依据支持其研发。需要共同努力来确定更好的临床获益预测生物标志物并提高治疗指数。临床医生需要更好地理解耐药机制，为合适的联合治疗方案和给药方案提出新的假设，开发更准确的模型系统，并开展创新性临床试验。
